Download PDF
1 / Pages

Other users also viewed these articles

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure Francisco J. Blanco; Esteban Rubio-Romero; Raimon Sanmartí; César Díaz-Torné; Pablo Talavera; Jochen Dunkel; Esperanza Naredo;
Reumatol Clin. 2020;16P1:345-52
Fibromyalgia with elevated rheumatoid factor is associated with poor therapeutic response but not with progression to rheumatoid arthritis. Prospective cohort study Freddy Liñán Ponce; Juan Leiva Goicochea; David Sevilla Rodríguez; Elmer Hidalgo Bravo; Ginna Obregón Atanacio; Inés Loyola Macalapú; Paola Jáuregui Rojas; Jackeline Yampufe Canani;
10.1016/j.reumae.2024.10.001
Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis? Ana Martins; Sofia Pimenta; Daniela Oliveira; Rafaela Nicolau; Alexandra Bernardo; Teresa Martins Rocha; Lúcia Costa; Miguel Bernardes;
Reumatol Clin. 2024;20:380-5